Role of the human microbiota and probiotics

$1,454,306ZIAFY2023AINIH

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications, trials & patents

Paper 38518792 Paper 36941053 Paper 36898551 Paper 36646104 Paper 35384360 Paper 35123653 Paper 34065548 Paper 33995317 Paper 33630954 Paper 33522395 Paper 32503672 Paper 32298967 Paper 31866425 Paper 30954574 Paper 30936487 Paper 30117414 Paper 29633455 Paper 29541068 Paper 29507878 Paper 28748707 Paper 28596942 Paper 28377905 Paper 28151994 Paper 27597849 Paper 27160595 Paper 26588783 Paper 26584249 Paper 26579084 Paper 25964472 Paper 25712972 Paper 25701233 Paper 25624333 Paper 25505739 Paper 25214518 Paper 25212723 Paper 24581690 Paper 24514089 Paper 24466348 Paper 24447915 Paper 24222457 Paper 24222452 Paper 23261595 Paper 23165978 Paper 22906361 Paper 22896791 Paper 22830599 Paper 22522561 Paper 22232686 Paper 22095240 Paper 21966513 Paper 21510745 Paper 21173311 Paper 21135501 Paper 20949069 Paper 20660682 Paper 20473345 Paper 20404927 Paper 20402773 Paper 20179594 Paper 19893740 Paper 19710683 Paper 19649313 Paper 19620329 Paper 19609257 Paper 18287750 Paper 18182108 Paper 17890122 Paper 17559115 Paper 17517597

Abstract

In FY 2023, our main endeavor in this project was to follow up on our 2018 finding that Bacillus subtitlis spores can be given to mice to eradicate S. aureus intestinal colonization, which is based on our observation that bacillal quorum-quenching lipopeptides inhibit S. aureus quorum-sensing, which we also found is essential for intestinal colonization. We set up and completed a clinical trial in healthy S. aureus-colonized volunteers in Thailand, who were given B. subtilis probiotic spores. This treatment, in this phase 2 double-blind, placebo-controlled trial, resulted in > 95% reduction in the overall numbers of S. aureus colonizing the human body without affecting the intestinal microbiome.

View original record on NIH RePORTER →